Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innovent Biologics Inc (OP: IVBXF )

5.350 +0.084 (+1.60%)
Streaming Delayed Price Updated: 2:16 PM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,450
Open 5.270
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 5.266
Today's Range 5.270 - 5.350
52wk Range 3.550 - 6.410
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was... 
Via Talk Markets
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to... 
Via Talk Markets

Performance

YTD
-0.93%
-0.93%
1 Month
+9.18%
+9.18%
3 Month
+22.99%
+22.99%
6 Month
+11.46%
+11.46%
1 Year
+26.48%
+26.48%

More News

Read More
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
Via Talk Markets
Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals
Via Talk Markets
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Via Talk Markets
Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China
Via Benzinga
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Via Talk Markets
Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform
Via Talk Markets
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Via Talk Markets
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
Via Talk Markets
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
Via Talk Markets
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
Via Talk Markets
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
Via Talk Markets
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
Via Talk Markets
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
Via Talk Markets
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
Via Talk Markets
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
Via Talk Markets
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
Via Talk Markets
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
Via Talk Markets
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Via Talk Markets
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
Via Talk Markets
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
Via Talk Markets
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
Via Talk Markets
Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
Via Talk Markets
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.